• Bioanalysis
  • All Things Oligonucleotides!

    The therapeutic development of antisense oligonucleotides (ASOs) has expanded its reach to encompass diseases like Huntington's, Alzheimer's, and Parkinson's.

    Given their ability to pinpoint disease pathogenesis's root cause, ASOs are a hopeful avenue for addressing stubborn illnesses and genetic disorders.

    Explore our resource library to learn more about oligonucleotides and their potential, from synthesis techniques to innovative applications.

    Poster Presentations:

    Application of Mitra Microsampling for the Quantitative Bioanalysis of ASOs 
    Development of a Surrogate Cerebrospinal Fluid Matrix for Quantitative Analysis of ASOs by Hybridization LC-MS 
    Development of an Oligonucleotide Drug Immunogenicity Assay 


    Bioanalytical Development for the Analysis of ASOs

    Special Issue of The Altascientist:

    Antisense Oligonucleotides (with two case studies!)

    Research Articles:

    A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA in Plasma, CSF, and Tissue Samples

    Accurate Quantification of ASOs in Mouse Serum Using Microsampling LC-MS/MS

    Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.

    Altasciences' Facilities: Moving in Unison

    Choosing the right bioanalytical platform for your molecule’s intended use and program segment is crucial to obtaining reliable, robust data in a timely manner. At Altasciences, our bioanalytical experts will determine the best approach for sample processing and analysis according to your molecule.


    Microsampling for Pediatric Baricitinib Pharmacokinetics

    Accurate Quantification of ASOs in Mouse Serum Using Microsampling LC-MS/MS

    A Bioanalysis Partner You Can Trust

    At Altasciences, we specialize in diverse immunomodulators, including proteins, oligonucleotides, biologics, bispecific antibodies, and gene therapy.

    Our evaluations count on essential biomarkers, like cytokines, complement factors, immune cell subtyping, and functional measurements.

    Rely on us for:

    • precise drug quantitation and biomarker assessment;
    • state-of-the-art bioanalytical platforms to monitor multiple aspects of     immunomodulation in various species;
    • bioanalytical teams with relevant experience handling pathogens and working with infectious samples for your vaccine development programs; and
    • labs equipped with containment Level 2 (CL2) areas for handling pathogens within the Risk Group 2.


    Need more guidance? Send us a message.

    You may also be interested in the below resources: 

    • eBook: Key Biomarkers of Immunomodulation: Complement Factors and Cytokines
    • Webinar: Development of a Cell-Based Assay for Dual Purposes
    • Webpage: Bioanalytical Platforms

    Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.

    You have questions; we have answers.

    Email not displaying correctly? View it in your browser.

    When you need quick answers to your burning questions, simply ask an Altascientist.   

    Chris McEvoy

    How does Altasciences expedite the process for acquiring CITES permits?  
    Watch the video »
    Connect with Chris »

    Scott Boley

    What are the advantages of selecting the miniature swine as a non-rodent model?
    Watch the video »
    Connect with Scott »

    Mathieu Saulnier

    Why is it important to have an in-house team dedicated to bioanalytical equipment?
    Watch the video »
    Connect with Mathieu »

    Lisa Sanford

    Do I need an IND before starting my FIH trial in Canada?
    Watch the video »
    Connect with Lisa »

    Roland Jbeily

    What should sponsors know about Canada’s regulatory requirements for CTA filings?
    Watch the video »
    Connect with Roland »

    Scott Boley

    What factors should sponsors consider when selecting a non-rodent alternative in their nonclinical studies?
    Watch the video »
    Connect with Scott »

    Ben Reed

    What do the recent expansions to Altasciences’ CDMO facility mean for current and future clients?
    Watch the video »
    Connect with Ben »

    Dennis DiBiagio

    How does Altasciences’ manufacturing site support the development of drugs that treat CNS disorders?
    Watch the video »
    Connect with Dennis »

    Submit a question
    See full video series

    Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

    Altasciences has been recognized as a 2023 CRO Leadership Award Champion in the Capabilities category, as voted by you in ISR’s annual CRO Quality Benchmarking survey.




    LinkedInLinkedIn   YouTubeYouTube   BlogBlog
    Preclinical   —   Clinical   —   Manufacturing and Analytical
    Bioanalysis   —   Research Support
    Copyright © {{Current_Year}}, Altasciences, All rights reserved.

    Our mailing address is:

    575 Armand Frappier
    Laval, H7V 4B3

    You are receiving this email because you are a friend of Altasciences, or have opted in via our website or while speaking to us at a recent event.

    Want to change how you receive these emails?
    You can update your preferences or unsubscribe from this list.


    To You, With Science - Our Latest Audiobook Releases

    Listen to the Latest Audiobook Releases of The Altascientist

    Delve deeper into the critical processes behind early phase drug development with audio versions of The Altascientist, written by our experts with you in mind:

    Issue 31 — The Advantages of Conducting Early Phase Clinical Research in Canada
    Find out you can accelerate your early phase clinical research by six to nine weeks in comparison with trials conducted in the U.S.
    Listen to the audiobook >>>

    Issue 32 — A Changing Paradigm for Non-rodent Species in Nonclinical Safety Studies
    Discover the increasing body of evidence that supports the use of miniature swine as a viable option for your small and large molecule studies.
    Listen to the audiobook >>>​​​

    Issue 33 — CNS Drug Development: Integrated Solutions Lessen Complexity
    Hear about the complexities of CNS drug development programs and how an integrated CRO/CDMO can help move your molecule seamlessly from one phase to the next.
    Listen to the audiobook >>>

     In Case You Missed It: 
    Issue 30 — The Evolution and Advancement of LCMS in Drug Development
    Learn how the latest LC-MS advancements ensure accurate and precise data delivery in your drug development program.
    Listen to the audiobook >>>

    Design and Validation of a Bioanalytical Method to Support a Clinical Pharmacokinetic Study Involving the Use of Multiple Lots of the Biological Therapeutic Drug

    Subscribe to Bioanalysis